Loading cancer entity…
Loading cancer entity…
Clinical trials
30 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (4)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03158064 | Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors | active not recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05529251 | De-escalation Study for Stage IIa/IIb < 3 cm Seminoma(EDEN) | recruiting | Phase 2 | 90 | Centre Leon BerardOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) | recruiting | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03937843 | Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma | active not recruiting | Phase 2 | 135 | Swiss Cancer InstituteOTHER | 2 | Jan 20, 2026 | clinicaltrials |
| NCT04876456 | A Phase II Trial of Cabozantinib With Patients With Refractory GCTs | active not recruiting | Phase 2 | 50 | Jennifer KingOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06144736 | PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND | recruiting | Phase 2 | 60 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT01593241 | Therapy De-escalation in Seminoma Stage IIA/B | terminated | Phase 2 | 120 | Swiss Cancer InstituteOTHER | 2 | Feb 13, 2025 | clinicaltrials |
| NCT01055067 | ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors | terminated | Phase 2 | 27 | Daiichi SankyoINDUSTRY | 3 | Apr 6, 2021 | clinicaltrials |
| NCT01037790 | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | completed | Phase 2 | 304 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT02272816 | Carboplatin AUC-10 With Early PET Scanning in Metastatic Seminoma(Car-PET) | completed | Phase 2 | 48 | Barts & The London NHS TrustOTHER | 1 | Jan 25, 2019 | clinicaltrials |
| NCT00957905 | Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2017 | clinicaltrials |
| NCT01887340 | Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma(SEMITEP) | unknown | Phase 2 | 271 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jun 9, 2016 | clinicaltrials |
| NCT01808534 | Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors | terminated | Phase 2 | 5 | Indiana UniversityOTHER | 1 | Jul 2, 2015 | clinicaltrials |
| NCT00042952 | Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer | terminated | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
Data updated 12 days agoSource updated Sep 18, 2026source: clinicaltrials